Technology
Health
Biotechnology

Radius Health

$20.64
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.22 (1.08%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell Radius Health and other stocks, options, ETFs, and crypto commission-free!

About

Radius Health, Inc. Common Stock, also called Radius Health, is a biopharmaceutical company, which engages in developing and commercializing endocrine therapeutics in the areas of osteoporosis and oncology. Read More The company's lead product, Abaloparatide-SC, reduces fracture risk in postmenopausal women with osteoporosis. Its pipeline also includes abaloparatide transdermal patch for potential use in osteoporosis and RAD1901 for potential use in hormone-driven, or hormone-resistant, metastatic breast cancer, and vasomotor symptoms in postmenopausal women. The company was founded by John Katzenellenbogen, Stavros C. Manolagas, Michael Rosenblatt, and John T. Potts on October 3, 2003 and is headquartered in Waltham, MA.

Employees
398
Headquarters
Waltham, Massachusetts
Founded
2003
Market Cap
948.76M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
745.54K
High Today
$20.78
Low Today
$19.55
Open Price
$20.20
Volume
163.33K
52 Week High
$31.92
52 Week Low
$12.81

Collections

Technology
Health
Biotechnology
Biopharmaceutical
Therapy
Cancer Prevention
Pharmaceutical
2014 IPO

News

Yahoo FinanceMay 9

Radius (RDUS) Posts Narrower Q1 Loss, Misses on Revenues

Radius Health, Inc. RDUS reported mixed results for the first quarter of 2019, wherein loss was narrower than expected but sales missed estimates. The company incurred a loss of 94 cents per share in the quarter, narrower than the Zacks Consensus Estimate of a loss of 95 cents and the year-ago loss of $1.11. The year-over-year improvement was backed by an increase in revenues. The company reported Tymlos’ sales of $29.8 million, missing the Zacks Consensus Estimate of $34.8 million. Quarter in Detail We...

12
Yahoo FinanceMay 9

Here’s What Hedge Funds Think About Radius Health Inc (RDUS)

Reputable billionaire investors such as Jim Simons, Cliff Asness and David Tepper generate exorbitant profits for their wealthy accredited investors (a minimum of $1 million in investable assets would be required to invest in a hedge fund and most successful hedge funds won't accept your savings unless you commit at least $5 million) by pinpointing winning small-cap stocks.

8
Seeking AlphaMay 8

Radius Health, Inc. CEO Jesper Høiland on Q1 2019 Results - Earnings Call Transcript

Radius Health, Inc. (NASDAQ:RDUS) Q1 2019 Earnings Conference Call May 8, 2019 8:00 AM ET Company Participants Elhan Webb - Head, IR & External Communications Jesper Høiland - President, CEO & Director Joseph Kelly - SVP, Sales & Marketing Charles Morris - Chief Medical Officer Jose Carmona - CFO, SVP & Treasurer Bruce Mitlak - Head, Clinical Development for Osteoporosis Conference Call Participants Jessica Fye - JPMorgan Chase & Co. Alec Stranahan - Bank of America Merrill Lynch Bradley Canino -...

0

Earnings

-$1.59
-$1.28
-$0.97
-$0.66
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 8, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.